Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibezapolstat in Recurrent Clostridioides Difficile Infection
NCT07513285Phase 2Recruiting
- Sponsor
- Acurx Pharmaceuticals, Inc.
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibezapolstat in Clostridioides difficile infection (CDI), sponsored by Acurx Pharmaceuticals, Inc.. Started Sep 2026; status: recruiting.
02
Drugs
ibezapolstat
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT07513285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513285.